Albireo Pharma (NASDAQ:ALBO) will be issuing its quarterly earnings data before the market opens on Thursday, February 25th. Analysts expect the company to announce earnings of ($1.98) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.
Shares of NASDAQ ALBO opened at $36.64 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 13.51 and a current ratio of 13.52. Albireo Pharma has a fifty-two week low of $11.26 and a fifty-two week high of $49.00. The stock has a market cap of $698.98 million, a PE ratio of -5.97 and a beta of 1.62. The stock has a fifty day moving average of $37.90 and a 200-day moving average of $35.37.
A number of research analysts have weighed in on the company. Zacks Investment Research raised Albireo Pharma from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 17th. Wedbush reaffirmed a “buy” rating and set a $66.00 price objective on shares of Albireo Pharma in a research note on Thursday, November 19th. Finally, HC Wainwright increased their target price on shares of Albireo Pharma from $67.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, December 18th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $64.25.
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Featured Article: What is a capital gain?
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.